Related Experiment Videos
Short-acting beta 2 agonists for stable chronic obstructive pulmonary disease
1Institute of Respiratory Diseases, University of Siena, Viale Bracci 3, 53100, Siena, Italy. sestini@unisi.it
The Cochrane Database of Systematic Reviews
|May 5, 2000
Summary
Short-acting beta-2 agonists provide slight improvements in lung function and breathlessness for Chronic Obstructive Pulmonary Disease (COPD) patients. While peak expiratory flow rates increased significantly, other measures like walking distance showed no consistent benefits in this review of randomized controlled trials.
Area of Science:
- Pulmonary Medicine
- Pharmacology
Background:
- Chronic Obstructive Pulmonary Disease (COPD) is characterized by progressive airflow limitation.
- Short-acting beta-2 bronchodilators are commonly used for symptomatic relief in COPD patients.
- This review focuses on inhaled short-acting beta-2 agonists in stable COPD management.
Purpose of the Study:
- To evaluate the clinical efficacy of inhaled short-acting beta-2 agonists versus placebo in stable COPD.
- To assess the adverse effects associated with these bronchodilators.
Main Methods:
- Systematic review of randomized controlled trials (RCTs).
- Searches conducted using the Cochrane Airways Group database and reference lists.
- Inclusion criteria: adult patients with stable COPD, minimum 7-day treatment, comparison with placebo.
Main Results:
- Thirteen high-quality, crossover design studies were included.
- Slight but significant improvements observed in FEV1 and FVC post-bronchodilator.
- Significant increases in morning and evening Peak Expiratory Flow Rate (PEFR).
- Significant reduction in breathlessness scores reported.
- No significant differences in FRC, airway resistance, or walking distance.
Conclusions:
- Inhaled short-acting beta-2 agonists offer modest improvements in lung function and symptom scores for stable COPD.
- Peak expiratory flow rates are significantly enhanced.
- Further research may be needed to clarify effects on exercise capacity and other parameters.